摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

O-beta-核糖基(1''-2')腺苷-5''-磷酸酯 | 28050-13-7

中文名称
O-beta-核糖基(1''-2')腺苷-5''-磷酸酯
中文别名
——
英文名称
O-β-D-ribofuranosyl-(1''-2')-adenosine-5''-O-phosphate
英文别名
[(2R,3S,4R,5S)-5-[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
O-beta-核糖基(1''-2')腺苷-5''-磷酸酯化学式
CAS
28050-13-7
化学式
C15H22N5O11P
mdl
——
分子量
479.34
InChiKey
OTKILVSIHNCMGB-ZQSHOCFMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    947.4±75.0 °C(Predicted)
  • 密度:
    2.29±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -4.5
  • 重原子数:
    32
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    245
  • 氢给体数:
    7
  • 氢受体数:
    15

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION
    申请人:Universität Basel
    公开号:EP3889602A1
    公开(公告)日:2021-10-06
    The invention relates to a method for modulating an interaction between an MR1 polypeptide and an MR1-specific T cell receptor molecule, whereby a MR1 polypeptide is contacted with a MR1 ligand compound that is a nucleobase adduct product reflecting a state of metabolic distress of a eukaryotic cell. The invention further relates to the use of compounds identified as MR1 ligands in vaccination or modulation of an MR1-restricted immune response.
    本发明涉及一种调节MR1多肽与MR1特异性T细胞受体分子之间相互作用的方法,其中MR1多肽与MR1配体化合物接触,MR1配体化合物是反映真核细胞代谢窘迫状态的核碱基加合物产物。 本发明进一步涉及鉴定为 MR1 配体的化合物在疫苗接种或调节 MR1 限制性免疫反应中的用途。
  • Synthesis and Properties of O-β-D-Ribofuranosyl-(1″-2′)-Adenosine-5″-O-Phosphate and Its Derivatives
    作者:Andrei A. Rodionov、Ekaterina V. Efimtseva、Sergey N. Mikhailov、Jef Rozenski、Ingrid Luyten、Piet Herdewijn
    DOI:10.1080/15257770008045465
    日期:2000.10
    The synthesis of O-beta -D-ribofuranosyl-(1"-2')-adenosine-5"-O-phosphate and its suitably protected derivative for oligonucleotide synthesis have been developed.
  • Synthesis of<i>O</i>-β-D-Ribofuranosyl-(1″-2′)-adenosine-5″-<i>O</i>-phosphate
    作者:Andrei A. Rodionov、Ekaterina V. Efimtseva、Sergey N. Mikhailov
    DOI:10.1080/15257779908041519
    日期:1999.4
    The first synthesis of O-beta-D-ribofuranosyl-(1 "-2')-adenosine-5 "-O-phosphate starting from protected 2'-O-beta-D-ribofuranosyladenosine has been performed.
  • [EN] MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION<br/>[FR] LIGANDS MR1 ET COMPOSITIONS PHARMACEUTIQUES POUR IMMUNOMODULATION
    申请人:UNIV BASEL
    公开号:WO2021144475A1
    公开(公告)日:2021-07-22
    The invention relates to a method for modulating an interaction between an MR1 polypeptide and an MR1-specific T cell receptor molecule, whereby a MR1 polypeptide is contacted with a MR1 ligand compound that is a nucleobase adduct product reflecting a state of metabolic distress of a cell. The invention further relates to the use of compounds identified as MR1 ligands in vaccination or modulation of an MR1-restricted immune response.
  • 10.1081/ncn-120022748
    作者:Efimtseva, Ekaterina V.、Shelkunova, Alexandra A.、Mikhailov, Sergey N.、Nauwelaerts, Koen、Rozenski, Jef、Lescrinier, Eveline、Herdewijn, Piet
    DOI:10.1081/ncn-120022748
    日期:——
    Abstract The efficient synthesis of Grp and Arp, minor tRNA components, has been developed.
    摘要已经开发出有效的合成Grp和Arp(tRNA的次要成分)的方法。
查看更多